Recruiting

Observational Study

Sponsor:

University of Pennsylvania

Code:

NCT00315380

Conditions

Eosinophilic Granulomatosis With Polyangiitis

Churg-Strauss Syndrome

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.

Conditions

Eosinophilic Granulomatosis With Polyangiitis

Churg-Strauss Syndrome

Study ID

NCT00315380

Start date

Apr, 2006

Status verified date

Aug, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study.

Parent or guardian willing to provide informed consent, if applicable

Exclusion Criteria:

\- Inability to give informed consent and to sign the consent form

Study Design

Enrollment

700 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Discover biomarkers in EGPA capable of measuring disease activity and response to treatment [ Time Frame: Study completion ]

Central Contacts and Locations

Locations

St. Joseph's Healthcare

Recruiting

Hamilton, Ontario, Canada

Contacts

Sandra Messier

905-522-1155smessier@stjoes.ca

Principal Investigator:

Nader A. Khalidi, MD

More Information

Sponsor

University of Pennsylvania

Last update posted

Aug 28, 2026

Last verified

Aug, 2026

Keywords

  • EGPA
  • CSS

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2026-08-28.